Latest News

A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial

A readout from the first late-stage clinical trial intended to treat the fatty liver disease known as NASH has delivered disappointing results.

Gilead Sciences said Monday that its experimental drug, called selonsertib, failed to improve liver scarring compared to a placebo in a Phase 3 clinical trial. The study enrolled nearly 900 patients with compensated cirrhosis, an advanced form of NASH at higher risk for liver-related death.

Read the rest…

Source link

Related posts

New analysis predicts top 25 US counties at risk for measles outbreaks


Insulet extends deal with Glooko in Europe


Medical News Today: What can cause a headache and a nosebleed?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy